{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:31:54Z","timestamp":1791203514726,"version":"4.2.0"},"reference-count":36,"publisher":"Informa Healthcare","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1185\/030079902125000787","type":"journal-article","created":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T22:06:28Z","timestamp":1033509988000},"page":"220-228","source":"Crossref","is-referenced-by-count":390,"title":["Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention"],"prefix":"10.1185","volume":"18","author":[{"given":"Vasilios G.","family":"Athyros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios A.","family":"Papageorgiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodosakis R.","family":"Mercouris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valasia V.","family":"Athyrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios N.","family":"Symeonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias O.","family":"Basayannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimokritos S.","family":"Demitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G.","family":"Kontopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3197","published-online":{"date-parts":[[2008,8,26]]},"reference":[{"key":"CIT0003","first-page":"1001","volume":"335","author":"Sacks FM","year":"1996","journal-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med"},{"key":"CIT0004","first-page":"1349","volume":"339","author":"Long-term Intervention with Pravastatin Ischemic Disease","year":"1998","journal-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.3.1333"},{"key":"CIT0006","first-page":"250","volume":"86","author":"Isaacsohn JL","year":"2000","journal-title":"Rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. Am J Cardiol"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2610"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00829-9"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1185\/0300799009117018"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01638-1"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.15.1446"},{"key":"CIT0013","first-page":"07","author":"Packard CJ","year":"1997","journal-title":"Circulation"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701163360301"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.13.1711"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04053-8"},{"key":"CIT0019","first-page":"34","volume":"17","author":"The Kolovou G.","year":"2001","journal-title":"Curr Med Res Opin"},{"key":"CIT0020","first-page":"25","volume":"82","author":"Bickel C","year":"2002","journal-title":"Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol"},{"key":"CIT0021","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-0037-1612902","volume":"85","author":"Joukhadar C","year":"2001","journal-title":"Thromb Haemost"},{"key":"CIT0022","first-page":"1933","volume":"103","author":"Jialal I","year":"2001","journal-title":"Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(00)90057-7"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.1.61"},{"key":"CIT0025","first-page":"2442","volume":"31","author":"Laufs U","year":"2000","journal-title":"Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199907000-00016"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(00)00746-2"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.65.1.14"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a015344"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.30.6.1410"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.19.2.436"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007017509008"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(98)00032-X"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199915010-00004"},{"key":"CIT0037","first-page":"C59","volume":"19","author":"Troche CJ","year":"1998","journal-title":"Eur Heart J"},{"key":"CIT0038","first-page":"332","volume":"336","author":"Johannesson M","year":"1997","journal-title":"Scandinavian Simvastatin Survival Study Group. N Engl J Med"},{"key":"CIT0039","first-page":"487","volume":"25","author":"Szucs TD","year":"2000","journal-title":"An analysis on the basis of the LIPID trial. Herz"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00641-9"},{"key":"CIT0042","first-page":"9","volume":"8","author":"Russell MW","year":"2001","journal-title":"Can J Clin Pharmacol"},{"key":"CIT0043","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/ajhp\/56.17.1726","volume":"56","author":"Elliott WJ","year":"1999","journal-title":"Am J Health Syst Pharm"}],"updated-by":[{"DOI":"10.1185\/03007995.2015.1057434","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T00:00:00Z","timestamp":1434585600000}}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/030079902125000787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T04:48:31Z","timestamp":1583729311000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1185\/030079902125000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2008,8,26]]},"published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1185\/030079902125000787"],"URL":"https:\/\/doi.org\/10.1185\/030079902125000787","relation":{"correction":[{"id-type":"doi","id":"10.1185\/03007995.2015.1057434","asserted-by":"object"}]},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}